SYNBIOTIC has revealed a strategic alliance with IRIS Capital Investment, so underlining a key turning point in its long-term expansion plan. A deeper strategic collaboration and a financial commitment included in the agreement are likely to help SYNBIOTIC to dominate the medical cannabis and industrial hemp industries all over Europe.
IRIS Capital investment’s boost
French venture capital firm IRIS Capital Investment, recognized for assisting publicly traded companies with tailored equity-linked financing solutions, has committed to subscribing to the convertible notes issued by SYNBIOTIC. The investment will be released in several tranches, with each tranche amounting to up to EUR 200,000. Consequently, the total value of the investment will reach EUR 2.4 million. At the end of April 2025, the first tranche is set to be released.
Unlike conventional financial deals, they are non-interest-bearing convertible bonds—a move that indicates mutual trust and a long-term vision from both parties. The partnership, according to Fabrice Evangelista, Managing Director of IRIS Capital, “goes far beyond simply financial support.” Evangelista underlined that the cooperation is based on common strategic objectives meant to speed up SYNBIOTIC’s growth and long-term expansion in a fast changing sector.
Synbiotic & IRIS: long-term vision
SYNBIOTIC CEO Daniel Kruse underlined the need of the cooperation, stressing IRIS Capital’s fit with the company’s expansion plans. According to Kruse,
“IRIS Capital Investment is a strong strategic partner with a long-term view. We are happy the IRIS management is sure of our expansion plan.”
This partnership promises more than simply money. SYNBIOTIC is well-positioned to seek new business prospects, expand its operations, and more confirm itself as a leading force in Europe’s developing legal cannabis sector given IRIS Capital’s tailored investment strategy and great expertise in equity financing.
At the next Talman event, “Shape the Future of Cannabis Investment,” on April 28, 2025, in Berlin, SYNBIOTIC is also getting ready to present its strategic plan to a worldwide investor audience. Panelist Daniel Kruse will offer analysis of SYNBIOTIC’s business model, expansion strategy, and the effects of strategic alliances—including one with IRIS Capital and another with GOC NEXUS. The organizer of the event, the Talman House, is a members-only network linking high-potential cannabis companies with experienced investors all throughout Europe and beyond.
GOC NEXUS and ICBC Berlin
SYNBIOTIC’s cooperation with GOC NEXUS, a partnership that started in December 2024, will be another major emphasis during the Talman event. Using a creative cold plasma technology, GOC NEXUS transforms cannabis raw materials into high-quality EU GMP-certified medical goods by means of microbial decontamination. This technology not only satisfies rigorous regulatory criteria but also does so in an environmentally responsible manner—an ever more important factor for consumers and manufacturers alike.
SYNBIOTIC and GOC NEXUS willt show again at the International Cannabis Business Conference (ICBC) in Berlin on April 29 and 30. ICBC Berlin is Europe’s largest B2B cannabis business event. It will attract politicians, business leaders, and entrepreneurs. This creates a great opportunity for SYNBIOTIC. They can showcase their latest partnerships and developments.
WEECO Pharma is a subsidiary of SYNBIOTIC Group, focusing on the wholesale of therapeutic cannabis. They will be at the ICBC partner booth. WEECO will meet trade visitors and potential customers as well as discuss the company’s capabilities. They will highlight the latest achievements. The product offering is steadily growing. WEECO Pharma’s performance has exceeded its yearly sales goals again. This adds to the momentum. The company maintains a pattern of constant outperformance. WEECO’s income numbers in December 2024 exceeded forecasts. This shows the rising demand for medical cannabis. It also highlights the SYNBIOTIC Group’s strong operations. WEECO plans to adjust its sales goals for 2025 to 2027. This change comes from ongoing success. The approach will be sensible and realistic. Expectations will remain reasonable and based on what can be achieved.
Synbiotic: looking forward
SYNBIOTIC is advancing and the business is on the rise. They are partnering with forward-thinking allies. They are exploiting growth in the European cannabis industry. IRIS Capital backs SYNBIOTIC with a strong partnership. It allows SYNBIOTIC to boost financial flexibility whilst new markets and technologies are on the horizon.
Companies like SYNBIOTIC focus on quality, they prioritize innovation and sustainability. These factors will help them become industry leaders. Regulatory frameworks around cannabis are changing in Europe and worldwide. This recent alliance with IRIS Capital is more than financial – it shows that SYNBIOTIC is preparing for faster growth. It aims for greater influence in health and wellness.